Takeda to sell GI 'gems' to earn European commission approval for Shire deal — 4 insights

Facing monopoly concerns, Takeda said it could sell Shire's developing gastroenterology therapy to gain European Commission approval, Reuters reports.

Here's what you should know:

1. Shire and Takeda are currently developing inflammatory bowel disease treatments. Shire's compound SHP647 is in phase 3 clinical trials. Takeda has its own IBD drug, Entyvio.

2. Takeda does not believe the concerns about a monopoly will delay the deal.

3. The European Union is the last regulatory body Takeda needs to win over to clear the deal. The company's shareholders still have to approve the deal.

4. Takeda's $62 billion acquisition will make it one of the world's largest and most indebted drug makers.

More articles on gastroenterology:
Dixie Regional Medical Center opens outpatient respiratory clinic — 3 notes
ASC supply chain tip of the day: Collaborate with sales reps
Drs. Richard Blumberg, Brent Lacey & more: 3 GI physicians making headlines

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months